Other Topics最新文献

{"title":"Abstract PO-051: PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma","authors":"V. Picozzi, T. Macarulla, P. Philip, C. Becerra, T. Dragovich","doi":"10.1158/1538-7445.panca21-po-051","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-051","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116073887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO-050: Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)","authors":"V. Picozzi, A. Duliege, A. Maitra, M. Hidalgo, A. Hendifar, G. Beatty, Sudheer Doss, Regina Deck, Lynn M. Matrisian, Julie M Fleshman, D. Simeone","doi":"10.1158/1538-7445.panca21-po-050","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-050","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122559313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO-048: A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer","authors":"C. Pan, Robert Tseng, S. Hogg, Gabriella Baraks, Cindy V Leiton, Lucia Roa-Peña, N. Marchenko, K. Shroyer, Luisa F. Escobar‐Hoyos","doi":"10.1158/1538-7445.panca21-po-048","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-048","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122191912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO-038: LAMC2: New player in stemness and tumor progression in pancreatic cancer","authors":"Donatella Delle Cave, Tea Teresa Iavazzo, M. Mangini, Gennaro Andolfi, T. Pirozzi, Annalisa Di Domenico, A. De Luca, E. Lonardo","doi":"10.1158/1538-7445.panca21-po-038","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-038","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129797560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO-041: Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells","authors":"D. Grygoryev, Taelor Ekstrom, Jason M. Link, R. Sears, Jungsun Kim","doi":"10.1158/1538-7445.panca21-po-041","DOIUrl":"https://doi.org/10.1158/1538-7445.panca21-po-041","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124298362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO-084: Genetic profiling of rat gliomas and cardiac schwannomas from cell phone radiofrequency radiation exposure using a targeted next-generation sequencing gene panel","authors":"R. Kovi, A. Vornoli, As Brooks, T. Ton, Miaofei Xu, E. Tibaldi, F. Gnudi, Jian-liang Li, R. Sills, J. Bucher, F. Belpoggi, A. Pandiri","doi":"10.1158/1557-3265.RADSCI21-PO-084","DOIUrl":"https://doi.org/10.1158/1557-3265.RADSCI21-PO-084","url":null,"abstract":"The cancer hazard associated with exposure to cell phone radiofrequency radiation (RFR) was examined using lifetime exposure in Sprague-Dawley (SD) rats at the Ramazzini Institute (RI), Italy. There were increased incidences of gliomas in the brain and schwannomas in the heart. In order to understand the translational relevance of these rat tumors for human disease, we examined the top 23 orthologous cancer genes mutated in human gliomas using a custom built a next-generation sequencing gene panel for rats based on Illumina’s TruSeq Custom Amplicon Technology. SD rat tissues (gliomas =15; cardiac schwannomas=9, interim (1 year) sacrificed non-tumor brain tissues from RFR exposed rats =30, control brain and heart control tissues from lifetime exposure=10 each, and age-matched control brain tissues from interim sacrificed rats=10) from the RI-RFR cancer bioassay were examined in this study. The deepSNV R-package with various filtering criteria and the read depth of >1000x were used to identify single-nucleotide variants (SNVs) in the rat gliomas and schwannomas. At 5% allelic frequency, there were an average of 43 SNVs per rat glioma and point mutations were detected in 9 genes (Arid1a, Cic, Tert promoter, Tp53, Atrx, Nf1, Pdgfra, Pi3kr1, and Setd2) in at least 3 or more rat gliomas based on population frequency. Five genes (Nf1, Tert promoter, Setd2, Arid1a, and Pdgfra) harbored SNVs in interim sacrificed brain tissues that were also present in RFR-exposed gliomas from lifetime exposure. Interestingly, no mutations were detected in hotspot regions of Idh1, Idh2, Egfr or Braf. In contrast to most human gliomas which harbor mutations in IDH1 and IDH2 genes, the rat gliomas seem to be Idh1 wild type with mutations in the other glioma-related genes. Primary cardiac tumors are extremely rare in humans. With this targeted NGS panel (at allelic frequency of 2.5%), there were an average of 146 SNVs per rat cardiac schwannoma and unique point mutations were detected in Cic, Egfr, Arid1a, Nf1, Setd2, Cdkn2a, Erbb2, Atrx, Pdgfra, and Notch1 in 3 or more cardiac schwannomas. A subset of the SNVs (Arid1a, Tp53, and Nf1) in rat gliomas was confirmed in human gliomas in the COSMIC database supporting the translational relevance of the rat gliomas for human disease. In addition, several SNVs from rat gliomas and cardiac schwannomas were found in various human cancers including carcinomas, hematopoietic neoplasms, melanomas and neuroendocrine tumors. In conclusion, the rat gliomas appear to share genetic alterations with a subtype of IDH1 wildtype human gliomas and rat primary cardiac schwannomas also harbor mutations in some of the queried cancer genes. Citation Format: Ramesh C. Kovi, Andrea Vornoli, Ashley Brooks, Thai Vu T. Ton, Miaofei Xu, Eva Tibaldi, Federica Gnudi, Jian-Liang Li, Robert C. Sills, John R. Bucher, Fiorella Belpoggi, Arun R. Pandiri. Genetic profiling of rat gliomas and cardiac schwannomas from cell phone radiofrequency radiation exposure usi","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126727236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract IA-022: Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter","authors":"D. Gius","doi":"10.1158/1557-3265.RADSCI21-IA-022","DOIUrl":"https://doi.org/10.1158/1557-3265.RADSCI21-IA-022","url":null,"abstract":"","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121399318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PO034: Long-term follow-up for a prospective phase II trial of levonorgestrel intrauterine device as non-surgical treatment for complex atypical hyperplasia and early endometrial cancer","authors":"Mikayla Waters, N. Pal, M. Woodall, J. Gallegos, S. Westin, M. Yates","doi":"10.1158/1557-3265.ENDOMET20-PO034","DOIUrl":"https://doi.org/10.1158/1557-3265.ENDOMET20-PO034","url":null,"abstract":"Background: The incidence of complex atypical hyperplasia (CAH) and early stage endometrioid endometrial cancer (EEC) is increasing. While standard upfront treatment for CAH and EEC is hysterectomy, non-surgical options are needed for the increasing population unable to undergo hysterectomy due to medical comorbidities precluding surgery or desired future fertility. Our recently published phase II trial of levonorgestrel intrauterine device (LIUD) showed substantial response for patients with CAH or grade 1 (g1) EEC, with 83% overall response rate at 12 months of LIUD treatment. Yet, relapse rates have not been well-defined in a large prospective clinical trial population. Further, we propose that estrogen-regulated gene expression biomarkers in the endometrium could reflect differences in estrogen signaling that drive later outcomes. Methods: This study was conducted under an approved IRB protocol at MD Anderson Cancer Center. Follow-up data for complete responders (those without evidence of hyperplasia or cancer following 12 months of LIUD) were abstracted from the medical record to determine long-term outcomes and relapse status (presence of CAH or grade 1 EEC). Estrogen-regulated gene expression biomarkers (PR, EIG121, IGF1, IGF2, RALDH2, survivin) were measured by real-time PCR from baseline endometrial biopsies and compared by relapse status. Results: Follow-up data were available for 30 of 39 participants that experienced complete response with 12 months of treatment with LIUD (median follow-up was 40 months). Eleven of 30 patients (36.7%) with complete response at the end of the 12-month LIUD treatment went on to experience relapse (6/23 with initial diagnosis of CAH and 5/7 g1 EEC). Median time to relapse after complete response was 14.3 months. Relapse occurred in patients with LIUD still in place (n=6) and LIUD removed (n=5). Of 11 cases with relapse, 5 subsequently responded to LIUD (including 3 cases with LIUD previously removed) and 6 went on to have hysterectomy. Two out of 30 (6.7%) complete responders showed progression of their initial g1 EEC lesions following the study: one patient progressed to grade 2 EEC and one patient progressed to grade 2 mixed EEC/clear cell carcinoma. Ten of 30 later had hysterectomy (equally from CAH and g1 EEC cohorts). Finally, although 13/30 patients indicated desired future fertility at baseline, only 3 attempted to conceive, and 1 achieved pregnancy and live birth. When comparing estrogen-regulated gene expression, participants that exhibited relapse had lower pre-treatment IGF1 than those that did not relapse (p=0.028). However, other biomarkers were not significantly different by relapse status. Conclusions: These findings show that although many patients with CAH or grade 1 EEC are initially responsive to LIUD, the response may not be durable. Additional studies are needed to evaluate biomarkers to predict risk of relapse and identify candidate targets for improved therapeutic strategies. Citat","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"146 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128947694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B28: Novel combination treatment designed to target both metastatic cells and proliferation in pancreatic ductal adenocarcinoma","authors":"Michelle N. Karl, Gabriella C. Russo, Bartholomew Starich, Haotian Tan, D. Wirtz","doi":"10.1158/1538-7445.PANCA19-B28","DOIUrl":"https://doi.org/10.1158/1538-7445.PANCA19-B28","url":null,"abstract":"Pancreatic cancer is the 4th most common cause of cancer-related deaths in the United States, with only a 7-9% 5-year survival rate. While there are a few combination treatments that have been shown to increase overall survival by several months, gemcitabine monotherapy, which has been used to treat PDAC since 2006, is still the most commonly administered first-line treatment. Our objective is to improve patient survival by providing a novel combination therapy designed to inhibit the growth of solid tumors and prevent metastatic cancer cells from reaching secondary organs. Our lab has recently shown that secreted interleukin 6 (IL-6) and interleukin 8 (IL-8) can induce a migratory phenotype in tumorigenic, metastatic cancer cells in triple-negative breast cancer models. Cells exposed to these cytokines display enhanced invasion through stromal environments, and this phenotype can be reversed by blocking the IL-6 and IL-8 receptors with the combined treatment of tocilizumab and reparixin. We hypothesized that this simultaneous blocking of IL-6 and IL-8 receptors would improve PDAC patient outcomes when used in combination with gemcitabine by targeting both proliferation and metastasis. Preliminary results show that this combination treatment has a positive effect in in vivo PDAC models. Our novel treatment combination was able to significantly reduce the tumor size, exceeding that seen from gemcitabine monotherapy. In addition, the triple combination reduced the metastatic burden and normalized the effect of the treatment among the mice in the group. Citation Format: Michelle Karl, Gabriella Russo, Bartholomew Starich, Haotian Tan, Denis Wirtz. Novel combination treatment designed to target both metastatic cells and proliferation in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B28.","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123728637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B35: Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging","authors":"J. Mizrahi, J. Rogers, G. Nogueras-Gonzalez, R. Wolff, G. Varadhachary, M. Javle, R. Shroff, Linus Ho, D. Fogelman, K. Raghav, M. Overman, S. Pant","doi":"10.1158/1538-7445.PANCA19-B35","DOIUrl":"https://doi.org/10.1158/1538-7445.PANCA19-B35","url":null,"abstract":"Background: Objective responses to first-line systemic chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC) are seen in less than one third of cases. While disease stabilization is achievable for a significant percentage, many of these pts will have radiographic evidence of disease progression (PD) on their first restaging imaging. With patients’ short life expectancy in the metastatic setting, limited systemic treatment options, and significant toxicities associated with multidrug chemotherapy, it is crucial for clinicians to be prudent when deciding whom and when to treat. The purpose of our study was to evaluate outcomes of pts who progressed on their first restaging imaging while on first-line therapy. Methods: We retrospectively analyzed mPC pts treated at MD Anderson since 2011 whose first restaging imaging on first-line therapy demonstrated PD. Data collected included patient demographics, choice of first-line therapy, and whether they received second-line therapy. Primary outcome was overall survival (OS) from date of metastatic diagnosis to death or last follow-up. Results: A total of 121 pts were included in the analysis. Seventy-two received second-line therapy, and 49 did not pursue second-line therapy. The median ages for pts who did and did not receive second-line therapy were 61 and 67, respectively (p=0.001). More pts had a poor Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 2-3) at the time of initial diagnosis in the non-second-line therapy group (31% vs. 6.9%, p=0.003). Forty-two pts (34.7%) received combination 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) first-line, while 72 pts (59.5%) received gemcitabine + nab-paclitaxel (GnP). Thirty-four pts (80%) who received FOLFIRINOX first-line did proceed with second-line therapy, and 29 pts (40%) who received GnP proceeded with second-line therapy. Median OS for those receiving second-line therapy was 8.28 months compared to 2.73 months for those not receiving second-line therapy (p Conclusions: Although likely biased due to better performance status and younger age, our mPC pts who progressed rapidly on first-line therapy showed an OS benefit if they received second-line therapy. These results suggest that pts maintaining a good performance status after immediate progression on first-line therapy should be offered second-line therapy. Citation Format: Jonathan D. Mizrahi, Jane E. Rogers, Graciela M. Nogueras-Gonzalez, Robert A. Wolff, Gauri R. Varadhachary, Milind M. Javle, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal P. Raghav, Michael J. Overman, Shubham Pant. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B35.","PeriodicalId":120683,"journal":{"name":"Other Topics","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124354812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}